With the commitment of being your best drug discovery partner, Creative Biolabs is capable of providing our clients with a variety of high-throughput screening services for discovering novel antimicrobial peptides. Equipped with a team of professional scientists, we have won a good reputation among our worldwide customers for successfully accomplishing numerous challenging projects in this field.
Surface localized antimicrobial display (SLAY), has been considered a high-throughput strategy for identifying novel antimicrobial peptides in the drug discovery process. Previous studies have demonstrated that antibiotics play an important role in preventing various types of antibiotic-resistant caused by different bacteria in patients. Meanwhile, pilot studies have also revealed that antimicrobial peptides have a broad spectrum of antibiotics capability against bacteria, fungi, or viruses. As a result, many attempts have been made to develop advanced techniques for screening peptide libraries and discovering new peptides. Among them, SLAY has been widely used for rapidly screening candidate antimicrobial peptides against Gram-negative bacteria. Recent researchers have indicated that the SLAY platform can express a large number of peptides with any sizes, sequences, and structures based on DNA sequencing technologies. Currently, the SLAY platform offers a unique opportunity for discovering lead peptides and aims to provide meaningful data for antibacterial drug discovery projects.
Fig.1 Surface Localized Antimicrobial Display Platform.
Nowadays, SLAY technology has shown promising results in identifying potential antimicrobial peptides and evaluating their ability to bind to target cells. As a professional antibacterial drug discovery company, Creative Biolabs has also generated our SLAY platform to offer a variety of custom services in peptide screening and function assessment for your target of interest. In general, a random peptide library has been established for selecting specific sequences to insert into the bacteria. Subsequently, the bacteria will be cultured for further expressing target peptides. The peptides with antibacterial functions will be selected from the whole system. Finally, sequences derived from different induction phases will be compared by using DNA sequence technology. Based on our SLAY platform, we have screened approximately 300,000 peptide sequences and have identified thousands of candidate potential antimicrobial peptides that have strong antimicrobial properties.
Fig.2 The workflow of surface localized antimicrobial display (SLAY). (Tucker, 2018)
Creative Biolabs is a leader in the field of antibacterial drug discovery for years. With in-depth expertise in peptide library construction, structural analysis, DNA sequence, as well as peptide function evaluation, we have developed a high-throughput SLAY platform service basing on a full range of state-of-art technologies. If you are interested in our services, please contact us for more details. Let us know what you need and we will accommodate you. We look forward to working with you in the future.
Reference
For Research Use Only.
